The many faces of hypoglycaemia in the paediatric population
Download
Report
Transcript The many faces of hypoglycaemia in the paediatric population
The many faces of
hypoglycaemia in the paediatric
population
Dr HC Yau
Prince of Wales Hospital
Case 1
• MHY
• Full term baby boy
• Birth weight 3.605 kg
• Uneventful antenatal course
• Third child of the family, healthy siblings
• No family history of note
• No consanguinity
• Presented with limbs twitching and startling response
since 17 days of life
• Increased in frequency
• Physical examination – hypotonia, liver 2-3 cm below
costal margin
• Plasma glucose 1.2 mmol/L
• Given bolus of dextrose, followed by dextrose infusion
with maximum glucose load at 12 mg/kg/min
Laboratory Results
Date
25/5/2005
31/5/2005
Glucose (mmol/L)
1.9
2.0
Insulin (mIU/L)
23.9
10.5
Growth Hormone
(mIU/L)
54
Cortisol (nmol/L)
311
Laboratory Results
• Urine metabolic screen and plasma amino acid profile
normal
• Lactate normal
• Ammonia – persistently high (253 – 334 umol/L) despite
normal glucose level and low protein diet
• Carnitine and acylcarnitine profile normal
• CT abdomen – apparent lobulation of body of pancreas
Treatment
• Initially started intravenous octreotide,
maximum at 26 mcg/kg/day
• Later switched to oral diazoxide 10
mg/kg/day and hydrochlorothiazide 2
mg/kg/day
Diagnosis
• Diagnosis – Hyperinsulinism
Hyperammonaemia Syndrome
• Genetic study – mutation detected in exon
10; Asn410Ile (N410I), represented by a
mutation of AAC to ATC at codon 410 in
GLUD1 gene
Congenital Hyperinsulinism
Introduction
• Heterogeneous disorder with respect to clinical
presentation, pancreatic histology and molecular biology
• Sporadic and familial
• Sporadic forms – relatively uncommon (incidence
1/40000 live births)
• Familial forms – common in communities with high rates
of consanguinity (incidence 1/2500 live births)
Clinical Presentation
• Typically present in first few days after birth
• Subtle forms may present later in infancy or
childhood
• Non-specific symptoms of hypoglycaemia such
as poor feeding, lethargy, irritability, seizures and
coma
• Macrosomia due to exposure to perinatal
hyperinsulinaemia
Diagnosis
• Hypoglycaemia (<2.6 mmol/L) with inappropriately raised
serum inuslin
• Low serum fatty acids levels and ketone bodies
• High intravenous glucose infusion rate, usually >8
mg/kg/min
• Serum lactate and ammonia may be elevated
• Urinary organic acid and acylcarnitine analysis (e.g. shortchain L-3-hydroxyacyl-CoA dehydrogenase (SCHAD)
deficiency)
Role of KATP channels in linking glucose
metabolism to regulated insulin
Pathophysiology
• Channelopathies
– Defects in pancreatic β-cell KATP channels
lead to unregulated insulin secretion
• Metabolopathies
– Increased β-cell ATP formation or
accumulation of intermediary metabolites,
triggering insulin secretion
Channelopathies
• Mutations in genes ABCC8 and KCNJ11
(encoding two subunits SUR1 and Kir6.2) of
pancreatic KATP channels
• Autosomal recessive mutations – commonest
genetic causes of congenital hyperinsulinism
• Autosomal dominant mutations also described
Metabolopathies
• Glutamate dehydrogenase
• Glucokinase
• Short-chain L-3-hydroxyacyl-CoA
dehydrogenase (SCHAD) deficiency
GDH and Regulation of Insulin
Secretion and Hepatic Ureagenesis
Summary of the known genetic causes of
hyperinsulinaemic hypoglycaemia
Intramitochondrial enzyme
catalyze β-oxidation of fatty
acids
Histology
• Diffuse form
– Affects all β-cells
– Most commonly due to
recessive mutations in
genes encoding two
subunits of KATP
channel
• Focal form (40-50%)
– Localised to one
region of pancreas
– Germline mutation in
paternal allele of
ABCC8 & KCNJ11
genes on chromosome
11p15.1 and somatic
loss of part of
maternally inherited
chromosome 11p15.5
Differentiating Focal from Diffuse
Congenital Hyperinsulinism
• In the past, invasive methods such as
intrahepatic pancreatic portal venous sampling,
intra-arterial calcium stimulation/venous
sampling test, acute insulin response testing to
intravenous glucose, calcium, and tolbutamide
• Recently, 18F-L-dopa PET scan successfully
used to localize focal disease
• Islets take up L-dopa and convert it to dopamine
by dopa carboxylase
European Case Series
•
18F-Dopa
PET scan identified 5 focal pancreatic lesions
in 14 patients with congenital hyperinsulinism
• These 5 patients operated, lesions matching PET scan
removed, became normoglycaemia
• Remaining 9 patients had diffuse disease in PET scan, 4
verified by histology while 4 consistent with pancreatic
catheterization
Diabetes 2006;55(1):13-18.
American Case Series
• 24 infants with hyperinsulinism unresponsive to medical
treatment
• Diagnosis of focal or diffuse disease by 18F-Dopa PET
scan correct in 23 of the 24 cases (96%) and equivocal
in 1 case
• 11 focal diseases confirmed by pathology and location of
lesions matched with PET scan in all cases (100%)
J Pediatr 2007;150:140-150.
Diffuse Disease
Focal Disease
Management
Hyperinsulinism
NH3
Diazoxide
PET scan
Focal
Diffuse
Glutamate
dehydrogenase
mutation
(Hyperinsulinism
Hyperammonaemia
Syndrome)
Octreotide
Partial pancreatectomy
Near-total pancreatectomy
Follow-up
Follow-Up
• Growth
• Neuro-development
• Diabetes mellitus management
• Pancreatic exocrine function
• Genetic counseling
Case 2
• ITL
• Presented at 4 years of age with fasting
hypoglycaemia
• History of stage IV peripheral T-cell lymphoma
arising from anterior mediastinum with
metastases to bone marrow and multiple bone
sites (basal skull, ribs, right femoral head and
left sacrum) at 3 years of age
• Treated according to ALL IC BFM 2002
high risk protocol
• In complete remission
• In maintenance phase chemotherapy with
methotrexate and 6-mercaptopurine
• Presented with 2 episodes of
hypoglycaemic attacks (sweating, malaise
and weakness) after prolonged fasting in
the morning without breakfast
• Symptoms resolved after taking food
• No more hypoglycaemic attack after
resuming breakfast everyday
Laboratory Results
• Fasting test – took 14 hours before developing
hypoglycaemia
• Plasma glucose 2.0 mmol/L, paired insulin 0.9 mIU/L
• Growth hormone 9.8 mIU/L, cortisol 1250 nmol/L
• Beta-hydroxybutyrate 2.0 mmol/L
• Lack of response to glucagon stimulation test – preglucagon glucose 2.4 mmol/L, post-glucagon glucose 2.0
mmol/L
Laboratory Results
• Lactate and ammonia normal
• Urine metabolic screen unremarkable except
large amount of ketones and reducing
substances
• Plasma amino acid profile normal
• Carnitine and acylcarnitine profile normal
Diagnosis
• Diagnosis – fasting hypoglycaemia related
to maintenance therapy
• 6-mercaptopurine and methotrexate
potentially affected hepatic
gluconeogenesis and glycogenolysis
Case Series from Finland
• 19 of 35 patients (54%) developed hypoglycaemia after 11 to 16
hours of fasting
• 14 of the 19 patients with hypoglycaemia (74%) <6 years of age
• No significant difference with respect to sex, height, body mass
index, doses of 6-mercaptopurine and methotrexate, duration of
therapy, or ALL risk group
• 15 of the 19 patients with hypoglycaemia re-tested 3 to 4 months
after cesation of maintenance therapy, all had improved fasting
tolerance
J Pediatr 2001;138:428-431
Case Series from Italy
• 6 of 86 patients developed total of 18
episodes of spontaneous hypoglycaemia
during treatment
• 5 of 6 patients are male, none >5 years of
age, 4 being only 3 years old
Med Pediatr Oncol 2002;39:32-34.
Summary
• Hypoglycaemia: a challenge to diagnosis
and treatment
• Careful history and investigations: PET
scan
• Meticulous control and follow up to reduce
CNS damage associated with recurrent
hypoglycaemia